Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $22 | $15 | $9 | $48 |
| - Cash | $6 | $2 | $4 | $24 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | $17 | $16 | $8 | $25 |
| Revenue | $15 | $14 | $16 | $17 |
| % Growth | 8.9% | -13.9% | -5.1% | – |
| Gross Profit | $9 | $8 | $10 | $13 |
| % Margin | 60% | 59.9% | 62.5% | 74.6% |
| EBITDA | -$11 | -$17 | -$24 | -$20 |
| % Margin | -70.2% | -120.8% | -152% | -115.7% |
| Net Income | -$11 | -$14 | -$24 | -$20 |
| % Margin | -74.1% | -98.4% | -148.8% | -120.2% |
| EPS Diluted | -2.22 | -11.14 | -25.9 | -23.89 |
| % Growth | 80.1% | 57% | -8.4% | – |
| Operating Cash Flow | -$13 | -$12 | -$20 | -$16 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$2 |
| Free Cash Flow | -$13 | -$13 | -$21 | -$18 |